These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 19114688)

  • 1. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
    Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
    J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
    J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
    Burgi A; Brodine S; Wegner S; Milazzo M; Wallace MR; Spooner K; Blazes DL; Agan BK; Armstrong A; Fraser S; Crum NF
    Cancer; 2005 Oct; 104(7):1505-11. PubMed ID: 16104038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
    Herida M; Mary-Krause M; Kaphan R; Cadranel J; Poizot-Martin I; Rabaud C; Plaisance N; Tissot-Dupont H; Boue F; Lang JM; Costagliola D
    J Clin Oncol; 2003 Sep; 21(18):3447-53. PubMed ID: 12972519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
    Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
    AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
    Stebbing J; Gazzard B; Mandalia S; Teague A; Waterston A; Marvin V; Nelson M; Bower M
    J Clin Oncol; 2004 Jun; 22(11):2177-83. PubMed ID: 15169806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
    Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
    Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS.
    Hessol NA; Pipkin S; Schwarcz S; Cress RD; Bacchetti P; Scheer S
    Am J Epidemiol; 2007 May; 165(10):1143-53. PubMed ID: 17344204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009.
    Calabresi A; Ferraresi A; Festa A; Scarcella C; Donato F; Vassallo F; Limina R; Castelli F; Quiros-Roldan E;
    HIV Med; 2013 Sep; 14(8):481-90. PubMed ID: 23560682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
    Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
    J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited impact of immunosuppression and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women.
    Heard I; Potard V; Costagliola D
    Antivir Ther; 2006; 11(8):1091-6. PubMed ID: 17302379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.
    Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Choisy P; Cochonat K; Fontier C; Guerroumi H; Ajana F; Chaud P; Yazdanpanah Y
    Antivir Ther; 2009; 14(4):567-75. PubMed ID: 19578242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growing problem of non-AIDS-defining malignancies in HIV.
    Pantanowitz L; Schlecht HP; Dezube BJ
    Curr Opin Oncol; 2006 Sep; 18(5):469-78. PubMed ID: 16894295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.